Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus Talaromyces sp. Against Hepatic Ischemia-Reperfusion Injury
Marine Drugs · 2025
DOI: 10.3390/md23080329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Wenxun Lan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutica…. Hauptthemen laut MEDLINE: Reperfusion Injury, Talaromyces, Liver, Protective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Project for Marine Economic Development of the Department of Natural Resources of Guangdong Province.
Abstract (Originalsprache)
A new trinor-sesterterpenoid penitalarin D (1), with a 3,6-dioxabicyclo[3.1.0]hexane moiety, as well as two known compounds, penitalarin C (2) and nafuredin A (3), were obtained from the mangrove sediment-derived Talaromyces sp. SCSIO 41412. Their structures were determined by detailed NMR, MS spectroscopic analyses, and ECD calculations. Penitalarin D (1) and nafuredin A (3) showed toxicity or no toxicity against HepG2 cells at a concentration of 200 μM. The transcriptome sequencing and bioinformatics analysis revealed that 3 could be effective by regulating ferroptosis pathways in HepG2 cells, which was subsequently validated by RT-qPCR, demonstrating significant upregulation of ferroptosis-related genes. Pre-treatment with 3 could mitigate hypoxia-reoxygenation-induced damage in the oxygen glucose deprivation/reperfusion (OGD/R) cell model. Given the structural similarity of compounds 1, 2, and 3, we also screened compounds 1 and 2 in an AML12 OGD/R model. As no significant activity was observed, compound 3 was selected for subsequent in vivo studies. Subsequently, in vivo experiments demonstrated that 3 could significantly decrease pro-inflammatory cytokines and display the hepatoprotective effects against hepatic ischemia-reperfusion injury (HIRI). These findings identified nafuredin A (3) as a promising hepatoprotective agent for new drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Guangdong Key Laboratory of Marine Materia Medica, State Key Laboratory of Tropical Oceanography, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of…
ORCID-Profile: Xuefeng Zhou
Förderung
- Special Project for Marine Economic Development of the Department of Natural Resources of Guangdong Province
Zitieren
APA
Lan, W., Cai, J., Yan, L., Wu, X., Zhang, L., Chen, C., Liu, Z., Zhou, X., & Tang, L. (2025). Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus Talaromyces sp. Against Hepatic Ischemia-Reperfusion Injury. Marine Drugs. https://doi.org/10.3390/md23080329
Vancouver
Lan W, Cai J, Yan L, Wu X, Zhang L, Chen C, et al. Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus Talaromyces sp. Against Hepatic Ischemia-Reperfusion Injury. Marine Drugs. 2025. doi:10.3390/md23080329
BibTeX
@article{Lan2025,
author = {Lan, Wenxun and Cai, Jian and Yan, Liyan and Wu, Xinyi and Zhang, Lisha and Chen, Chunmei and Liu, Zhongqiu and Zhou, Xuefeng and Tang, Lan},
title = {Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus Talaromyces sp. Against Hepatic Ischemia-Reperfusion Injury},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23080329}
}
EUVIMED